SCHEMBL5169717

SCHEMBL5169717

CCOC(=O)C(CCO)CCCO

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CPB2 Q96IY4 2/20 0.47
CYP4F2 P78329 3/20 0.43
CYP4A11 Q02928 3/20 0.43
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
ALDH1A1 P00352 2/20 0.37
KMT2A Q03164 4/20 0.37
MEN1 O00255 2/20 0.37
NPC1 O15118 1/20 0.37
HDAC3 O15379 1/20 0.36
HDAC4 P56524 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC7 Q8WUI4 1/20 0.36
HDAC2 Q92769 1/20 0.36
HDAC10 Q969S8 1/20 0.36
HDAC11 Q96DB2 1/20 0.36
HDAC8 Q9BY41 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
HDAC9 Q9UKV0 1/20 0.36
HDAC5 Q9UQL6 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6522112 0.92 CPB2 (0.51) CPB2CYP4F2CYP4A11CA1CA2
SCHEMBL17523695 0.89 HDAC1 (0.44) CPB2CYP4F2CYP4A11CA1CA2
SCHEMBL28078262 0.89 HDAC1 (0.44) CPB2CYP4F2CYP4A11CA1CA2
SCHEMBL5000143 0.88 CPB2 (0.47) CPB2CYP4F2CYP4A11CA1CA2
SCHEMBL1101304 0.86 CPB2 (0.51) CPB2CA1CA2LMNA
SCHEMBL15903982 0.86 CPB2 (0.51) CPB2CA1CA2LMNA
SCHEMBL28448275 0.86 CPB2 (0.51) CPB2CA1CA2LMNA
SCHEMBL15903942 0.86 CPB2 (0.51) CPB2CA1CA2LMNA
SCHEMBL11128494 0.86 CPB2 (0.51) CPB2CA1CA2LMNA
SCHEMBL9256335 0.86 CPB2 (0.60) CPB2CYP4F2CYP4A11CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117561268-A Targeting ligands and uses thereof 上海金中锘美生物医药科技有限公司 2024-02-13 CN disclosed
CN-116801886-A LPA inhibitors and uses thereof 上海金中锘美生物医药科技有限公司 2023-09-22 CN disclosed
WO-2023138664-A1 TARGETING LIGAND AND USE THEREOF 上海金中锘美生物医药科技有限公司 2023-07-27 WO disclosed
EP-1510356-B1 Imageable elements containing cyanoacrylate polymer particles EASTMAN KODAK CO (US) 2007-04-25 EP disclosed
US-7070902-B2 Imageable elements containing cyanoacrylate polymer particles EASTMAN KODAK COMPANY (US) 2006-07-04 US disclosed
US-20060093554-A1 Galenical formulations BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2006-05-04 US disclosed
US-20050074409-A1 Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of plaque, tumors and necroses BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2005-04-07 US disclosed
US-20050048396-A1 Imageable elements containing cyanoacrylate polymer particles KODAK (NEAR EAST) INC. 2005-03-03 US disclosed
EP-1510356-A1 Imageable elements containing cyanoacrylate polymer particles Kodak Polychrome Graphics, LLC (US) 2005-03-02 EP disclosed
US-6818203-B2 COMPLEXES HAVE CRITICAL MICELLE FORMATION CONCENTRATION, HYDRODYNAMIC MICELLE DIAMETER, AND PROTON RELAXIVITY IN PLASMA CONTRAST MEDIA IN MR IMAGING SCHERING AKTIENGESELLSCHAFT (DE) 2004-11-16 US disclosed
CN-1469757-A Use of metal complexes containing perfluoroalkyl as contrast agents in MR-imaging for the representation of plaques, tumours and necroses ���ֹɷݹ�˾ 2004-01-21 CN disclosed
US-20030072713-A1 Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of plaque, tumors and necroses BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2003-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030072713-A1 Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of plaque, tumors and necroses FABP3, PRF1, PTDSS1 CPB2 1933/4885CYP4F2 2853/4885CYP4A11 3548/4885
US-20050074409-A1 Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of plaque, tumors and necroses FABP3, PRF1, MALT1 CPB2 2498/4885CYP4F2 3095/4885CYP4A11 3069/4885
US-20060093554-A1 Galenical formulations GALC, GALR2, GALR1 CPB2 3330/4885CYP4F2 1851/4885CYP4A11 3391/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.